Scarica l'app Stockscreener
6.19
0.49%
0.03
Pre-mercato:
6.41
0.22
+3.55%
Y Mabs Therapeutics Inc Borsa (YMAB) Ultime notizie
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St
Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn
Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times
Y-mAbs Strengthens DANYELZA Team with Industry Veteran Doug Gentilcore as Business Unit Head - StockTitan
Y-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89 - MarketBeat
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA - Yahoo Finance
When (YMAB) Moves Investors should Listen - Stock Traders Daily
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp - Defense World
State Street Corp Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at J.P. Morgan Healthcare Conference 2025: Cancer Treatment Innovation Spotlight - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance
(YMAB) Trading Signals - Stock Traders Daily
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Australia
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Buy” by Brokerages - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P. - MarketBeat
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth - Simply Wall St
Equities Analysts Offer Predictions for YMAB FY2024 Earnings - MarketBeat
Brookline Capital Management Predicts YMAB FY2024 Earnings - Defense World
Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Trend Tracker for (YMAB) - Stock Traders Daily
Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting - StockTitan
United Rentals (URI-N) QuotePress Release - The Globe and Mail
Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation - MSN
Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Increased to Strong-Buy at Brookline Capital Management - MarketBeat
Decoding 5 Analyst Evaluations For Y-mAbs Therapeutics - Inkl
Pork Cutout (KMV25) Quote - The Globe and Mail
Nasdaq-100 Ex-Tech Sector Index (NDXX) QuotePress Release - The Globe and Mail
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):